Spearhead Bio raises $1.6M seed to fix CRISPR's big-DNA problem
What's the deal? Spearhead BioDealroom has a profile for this one. Try Dealroom → has closed an oversubscribed $1.62 million seed round to advance a genome engineering platform that inserts or replaces large pieces of DNA at targeted spots in crop genomes. BioGenerator VenturesDealroom has a profile for this one. Try Dealroom → and Danforth Technology Company (DTC)Dealroom has a profile for this one. Try Dealroom → led the round, with participation from Grit Road PartnersDealroom has a profile for this one. Try Dealroom →, QRM CapitalDealroom has a profile for this one. Try Dealroom →, SDH CapitalDealroom has a profile for this one. Try Dealroom →, and the St. Louis Port Authority Helix Fund.
Why now? The round comes a couple of years after Spearhead launched out of DTC, a subsidiary of the Donald Danforth Plant Science CenterDealroom has a profile for this one. Try Dealroom → in St. Louis, Missouri. The new capital gives the company runway to hit technical milestones.
What's the endgame? Spearhead's Transposase Assisted Homology Independent Targeted Insertion (TAHITI) technology targets a known CRISPR weakness. CRISPR excels at cutting DNA but struggles to insert new material precisely, often placing it at random and disrupting plant function.
How it works: Spearhead fuses a transposable element directly to CRISPR's molecular scissors, Cas9 or Cas12a, so new genetic cargo glues into the cut precisely. CEO Mike Bielski likens CRISPR to swapping single letters in a word, while TAHITI can move whole sentences. The platform can stack traits or fully replace genes across transgenic and non-transgenic crops.
Why it matters: Non-transgenic applications could open a faster, cheaper regulatory path. "Instead of having an additional three years and $80 million to get a trait through deregulation, it's going to be much faster," claims founder Keith Slotkin. He says the technology "saves our partners years of development time and millions of dollars in crop improvement."
The signal: The $1.62 million seed sits in the 32nd percentile for size, a modest early bet. But it reflects growing investor interest in tools that push crop gene editing beyond CRISPR's current limits.
Read more: agfundernews.com
Image credit: Spearhead Bio
